Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]AG-120
- Development stage
- Preclinical
- Lead developer
- Helmholtz-Zentrum Dresden-Rossendorf
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
[18F]AG-120 is a fluorine-18 labeled radiopharmaceutical tracer developed for positron emission tomography (PET) imaging of mutant isocitrate dehydrogenase 1 (mIDH1) in gliomas. It is a radiolabeled derivative of ivosidenib (AG-120), an FDA-approved small molecule inhibitor of mIDH1. Developed by researchers at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) and ROTOP Pharmaka, [18F]AG-120 is designed to non-invasively assess the IDH1R132H mutation status in brain tumors, aiding in patient stratification and treatment monitoring. Preclinical studies have demonstrated target-specific internalization in vitro and high metabolic stability in vivo, although its blood-brain barrier penetration is limited unless co-administered with a P-glycoprotein inhibitor like cyclosporine A.
- Other names
- 18F-AG-12018F-AG12018F-ivosidenib[18F]ivosidenib
02
Targets
IDH1 (Isocitrate dehydrogenase [NADP] cytoplasmic)
Beyond the preview
Go deeper on [18F]AG-120.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [18F]AG-120.